LEXINGTON, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group and M-Vest on Wednesday, January 25, 2023.
Ms. Curley will present at 8:30 a.m. ET. To attend, please register here.
For more information about the conference, or to schedule a one-on-one meeting with iSpecimen’s management team, please contact your appropriate Maxim representative, or send an email to KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.92 |
Daily Change: | -0.08 -7.60 |
Daily Volume: | 770,866 |
Market Cap: | US$7.550M |
August 04, 2025 January 16, 2025 December 20, 2024 December 13, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load